AbbVie (NYSE: ABBV) — Company Overview, News & Financial Data
AbbVie is a biopharmaceutical company focused on innovative therapies for complex health issues in multiple therapeutic areas.
ABBV AbbVie
Company profile
AbbVie
AbbVie is a research-based biopharmaceutical company focused on discovering, developing, and delivering medicines and therapies across key therapeutic areas, including immunology, oncology, neuroscience, eye care, and aesthetics. Headquartered in North Chicago, Illinois, the company operates research and development centers and manufacturing facilities globally, addressing complex health conditions for patients worldwide. AbbVie delivers commercial pharmaceutical products and aesthetic treatments across global markets through clinical research, manufacturing networks, and strategic industry partnerships.
Snapshot
Public USOwnership
2012Year founded
~57,000Employees
North Chicago, United StatesHead office
Loading Map...
Global footprint
Operations
Products and/or services of AbbVie
- Immunology: Research, development, and commercialization of targeted biological and oral therapies for complex autoimmune and inflammatory disorders, including Skyrizi, Rinvoq, and Humira, treating conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- Oncology: Development and commercialization of targeted cancer therapies, including antibody-drug conjugates and multispecific medicines for blood cancers and solid tumors, featuring major commercial therapies such as Imbruvica, Venclexta, and Elahere across global markets.
- Neuroscience: Provision of specialized pharmaceutical treatments for complex central nervous system and psychiatric conditions, including therapeutic products for chronic migraine, Parkinson's disease, major depressive disorder, and schizophrenia, featuring therapies like Vraylar and Botox Therapeutic.
- Aesthetics: Development and distribution of medical aesthetic products under Allergan Aesthetics, including facial injectable treatments, dermal fillers, and body contouring technologies such as Botox Cosmetic and the Juvederm product family supplied to healthcare providers worldwide.
- Eye Care: Commercialization of specialized ophthalmic treatments and pharmaceutical therapies targeting serious ocular conditions, including glaucoma, dry eye disease, and retinal disorders, serving clinical practices and patients across major global pharmaceutical markets.
- Contract Manufacturing: Provision of custom biopharmaceutical development and contract manufacturing services to global partner companies, offering formulation, biologics manufacturing, drug product fill-finish, and active pharmaceutical ingredient synthesis across state-of-the-art facilities.
AbbVie executive team
- Robert A. MichaelCEO & Chairman of the Board
- Scott T. ReentsExecutive VP & CFO
- Azita SalekiExecutive VP & COO
- Roopal B. ThakkarExecutive VP of Research & Development and Chief Scientific Officer
- Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer
- Linda RaySenior VP & Chief Information Officer
- Elizabeth SheaSenior Vice President of Investor Relations
- Perry C. SiatisExecutive VP, General Counsel & Secretary
- Demetris D. CrumExecutive VP & Chief Human Resources Officer
- Wulff-Erik von BorckeSenior VP & President of Oncology
Latest news about AbbVie
AbbVie reports 40.5% Crohn's remission with ABBV-466
United StatesAbbVie secures two FDA Breakthrough Therapy Designations for Temab-A
United StatesAbbVie reports ABBV-295 Phase 1 weight loss data
United StatesAbbVie presents 60 dermatology study updates at EADV
United StatesAbbVie reports positive Phase 2 results for zumilokibart
United StatesAbbVie wins FDA approval for Parkinson’s drug
United States
Dividend history
Dividends per share paid by AbbVie, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $6.9200 |
| FY2025 | — | — | — | $6.5600 |
| FY2024 | — | — | — | $6.2000 |
| FY2023 | — | — | — | $5.9200 |
| FY2022 | — | — | — | $5.6400 |
Key financials
Reported results for AbbVie, in USD.
- Market cap
- 505.4B
- Revenue (TTM)
- 64.4B
- P/E ratio
- 80.8
- EPS (diluted, TTM)
- 3.5
- Dividend yield
- 2.4%
- Profit margin
- 9.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 61.2B | 20.1B | 4.2B | |
| 56.3B | 9.1B | 4.3B | |
| 54.3B | 12.8B | 4.9B | |
| 58.1B | 18.1B | 11.8B |